iiinova — where your digital self keeps evolving

Ajay Major, MD, MBA @majorajay.bsky.social · 11/09/2026

Elated to share that our NCI K08 has been selected for funding! Deeply grateful to @hawkeyestudts.bsky.social and my colleagues @cuhematology.bsky.social @accordsresearch.bsky.social for their persistence and coaching in bringing this lymphoma PRO-focused training award to fruition. #lymsm

140

Reposted by Ajay Major, MD, MBA

CU Anschutz Cancer Center @cucancercenter.bsky.social · 03/09/2026

In a new study, Ajay Major (@majorajay.bsky.social), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF

Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.

073

Reposted by Ajay Major, MD, MBA

Mark Harden @markharden.bsky.social · 02/09/2026

CAR T-cell therapy has revolutionized treatment of stubborn cancers. Now, a groundbreaking study from @cucancercenter.bsky.social researchers addresses “a huge unanswered gap” in how CAR T-cell therapy impacts patients over two years. @cuanschutz.bsky.social @majorajay.bsky.social #cucityofhealth

news.cuanschutz.edu

CAR T-Cell Therapy is a Blood Cancer Breakthrough. But What About Quality of Life?

A CU Anschutz Cancer Center member and a resident physician study how patients feel two years after CAR T-cell therapy.

022

Ajay Major, MD, MBA @majorajay.bsky.social · 01/09/2026

Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social. Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵 doi.org/10.1016/j.bn...

152

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

Multicenter international SCNSL outcomes 🧵 @cwynkate2.bsky.social: - 1139 pts, 35 centers: 537 de novo SCNSL, 395 isolated CNS relapse, 207 synch CNS/systemic dx - 2-yr PFS: 40% de novo, 44% CNS isolated, 16% synch (!!) - CNS isolated w/ very low risk of systemic dx (6%) #lymsm 1/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 17/08/2026

RW epcoritamab R/R aNHL outcomes (CUBIC Consoritum) @bloodadvances.bsky.social: - 157 pts, 9 centers, med age 70, 55% prior CAR - 46% EPCORE NHL-1 ineligible - ORR 50% (CR 32%) - mPFS 3.5 mos, mOS 7.6 mos; 1-yr PFS/OS 29%/38% 1/2

100

Ajay Major, MD, MBA @majorajay.bsky.social · 10/08/2026

Mosun/pola in R/R MCL post BTKi @BloodPortfolio - 42 pts, 67% high Ki67, 48% TP53mut, 26% prior CAR - ORR 88% (CR 79%), post-CAR ORR 91%, TP53mut ORR 100% - mPFS 18.6 mos, mOS 20.7 mos - CRS 43% (all G1-2), ICANS 7% (all G1-2) - 5 (12%) G5 infection-related AEs (3 COVID, 1 WNV, 1 PNA) #oncsky 1/2

111

Ajay Major, MD, MBA @majorajay.bsky.social · 08/08/2026

Congratulations to my mentee Dr. Elisa Hofmeister @cuinternalmed.bsky.social on publication of this comprehensive review of patient-reported outcomes from novel lymphoma immunotherapies. Harmonized PRO and tolerability measurement frameworks are needed. #lymsm pubmed.ncbi.nlm.nih.gov/42565955/

121

Ajay Major, MD, MBA @majorajay.bsky.social · 04/08/2026

Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org. CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."

232

Ajay Major, MD, MBA @majorajay.bsky.social · 03/08/2026

Fixed-duration ven after cBTKi progression in CLL @bloodjournals.hematology.org - 79 pts, 71% VR, 82% 2/3L, 20% TP53mut - ORR 78% (CR 41%) - 18-mo PFS 79%, TTNT 80%, OS 84% - VR subgroup: 18-mo PFS 78%, OS 87% - VO subgroup too small Good RW data to support tx sequencing. #oncsky #medsky

141

Reposted by Ajay Major, MD, MBA

ACCORDS @accordsresearch.bsky.social · 14/07/2026

Congratulations to Ajay Major, MD, MBA, who is the lead author on a new publication from The Oncologist! Read Now: tinyurl.com/3src42t6 #ACCORDSIntegration #HealthServicesResearch #CancerResearch

$New Publication | "Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma" was published in The Oncologist by Ajay Major, MD, MBA, Assistant Professor, Department of Medicine, Division of Hematology.$

041

Ajay Major, MD, MBA @majorajay.bsky.social · 05/07/2026

TME may explain pola-R-CHP benefit in DLBCL #lymsm - post-hoc RNAseq analysis across 3 RCTs: >1200 pts - low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP - in M1-low pts, pola-R-CHP improved PFS v R-CHOP: HR 0.59 1/2

112

Ajay Major, MD, MBA @majorajay.bsky.social · 23/06/2026

Huge thank you to @cucancercenter.bsky.social for featuring our latest publication on patient-reported time toxicity from bispecific antibodies in FL & DLBCL, including how dosing schedules can meaningful impact time burden for patients & care partners. #lymsm news.cuanschutz.edu/cancer-cente...

news.cuanschutz.edu

Time Toxicity: Weighing the Benefits of Cancer Therapies Against Time Demands on Patients

A new study led by CU Anschutz Cancer Center member Ajay Major, MD, MBA, surveyed patients with relapsed lymphoma about the time burdens of treatments.

100

Ajay Major, MD, MBA @majorajay.bsky.social · 23/06/2026

Speaking today at the IVI PCORI-funded Convening on time toxicity in patients with cancer. Excited to highlight our latest publication on measuring time toxicity as a patient-reported outcome: academic.oup.com/oncolo/artic... #lymsm #oncsky

010

Ajay Major, MD, MBA @majorajay.bsky.social · 22/06/2026

5-year CLL13/GAIA follow-up: - 5-yr PFS: GIV 81%, GV 70%, RV 57%, CIT 51% - no OS differences - figure has uIGHV (B) vs mIGHV (C) - cardiac AEs highest with GIV - GV/RV had faster QoL improvements vs CIT; GIV QoL gains occurred later (more tx-related side effects) 1/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 16/06/2026

Super important data: PROs for R-pola-glo unfit 1L LBCL #lymsm - 80 pts, med age 80, 91% frail - high PRO completion >80% Despite frailty, clinically-meaningful QoL improvements: - global QoL during tx; 44% w/ sig improvement by C4 - physical function/fatigue maintained - emotional QoL improved 1/

100

Ajay Major, MD, MBA @majorajay.bsky.social · 15/06/2026

RW epcor R/R LBCL outcomes (CUBIC Consortium): - 157 pts, 55% prior CAR, 46% trial ineligible - ORR 50%, CR 32% - mPFS 3.5 mo, mOS OS 7.6 mo - 1-year PFS 29%, 1-year OS 38% - ⬇️survival: poor PS,⬆️LDH, refractory, trial ineligible 1/ #lymsm pubmed.ncbi.nlm.nih.gov/42263668/

111

Ajay Major, MD, MBA @majorajay.bsky.social · 10/06/2026

The latest findings from our ongoing BISON-PRO Quality of Life Study (bison-pro.org): measuring financial toxicity in patients with lymphoma & CLL from active surveillance through treatment and survivorship. Manuscripts forthcoming! #lymsm cc @cuhematology.bsky.social bison-pro.org/new-bison-pr...

bison-pro.org

New BISON-PRO Findings: Understanding Financial Stress in People with Lymphoma - BISON-PRO Quality of Life Study

We would like to share new findings from the BISON-PRO Quality of Life Study, focused on financial toxicity in people living with lymphoma and CLL.

000

Ajay Major, MD, MBA @majorajay.bsky.social · 31/05/2026

Frontline H. pylori eradication for extragastric ENMZL #lymsm - 26 pts, 46% conjunctival, 19% parotid - ORR 65% (CR 39%, PR 27%), time to CR 6 mos - 7-yr EFS 77%, OS 96% - HP+ dx with better responses (obv), t(11;18) less responses Provocative evidence re: HP+ in non-gastric sites...

100

Ajay Major, MD, MBA @majorajay.bsky.social · 28/05/2026

Fixed-duration SC mosun older/unfit 1L DLBCL #ASCO26 - median age 83 (71-101!), 53% IPI 3-5 - ORR 74%, CR 59% - 12-mo PFS 71%, OS 75% - CRS 12% (all G1-2), 49% infx (16% G3), 8% G5 AEs - PROs: 53% w/ improvements in lymphoma sx #lymsm

122

Ajay Major, MD, MBA @majorajay.bsky.social · 28/05/2026

Hans IHC vs GEP for DLBCL COO classification #EHA2026 Large meta-analysis (19 studies, 2247 tumors) to eval noninferiority of Hans IHC to GEP. Estimated accuracy: - Hans IHC 90% - pooled GEP 95% - 4.5% difference met noninferiority margin - sens 6.5% / NPV 6.4% library.ehaweb.org/eha/2026/eha...

library.ehaweb.org

A SYSTEMATIC ASSESSMENT OF DLBCL CELL-OF-ORIGIN CLASSIFICATION... by Ash Alizadeh

EHA Library; Alizadeh A. May 12 2026; 4210285;

110

Ajay Major, MD, MBA @majorajay.bsky.social · 24/05/2026

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) #lymsm #oncsky

100

Ajay Major, MD, MBA @majorajay.bsky.social · 23/05/2026

Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL #lymsm - 120 pts actively receiving BsAb tx - fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco) - no difference in infusion time between IV and SQ academic.oup.com/oncolo/advan...

120

Ajay Major, MD, MBA @majorajay.bsky.social · 21/05/2026

Congratulations to our Major Lab member Keegan Carroll on his abstract at @accordsresearch.bsky.social COPRH Con on patient-reported financial toxicity in patients with lymphoma. Look out for the future manuscript! #lymsm @cucancercenter.bsky.social @cuanschutz.bsky.social @cuhematology.bsky.social

011

Ajay Major, MD, MBA @majorajay.bsky.social · 21/05/2026

Eager to be presenting at the @accordsresearch.bsky.social COPRH Con today on pragmatic use of PROs in cancer research! Joined by Drs. Sarah Tevis, Tyler Buckner, & Allison L'Hotta. #PRO #QoL cc @cuanschutz.bsky.social @cucancercenter.bsky.social @cuhematology.bsky.social

000

Ajay Major, MD, MBA @majorajay.bsky.social · 12/05/2026

Prebiopsy steroids & diagnostic yield DLBCL #lymsm - 320 pts - yield unchanged w/ steroids (83% v 81%) - no association w/ dose/duration - no delay in time to treatment - FNA less diagnostic than excisional/incisional - core needle 12% less likely to be diagnostic jamanetwork.com/journals/jam...

jamanetwork.com

Prebiopsy Steroids and Diagnostic Yield in Diffuse Large B-Cell Lymphoma

This cohort study evaluates whether corticosteroid use before biopsy is associated with the diagnostic yield in patients with newly diagnosed diffuse large B-cell lymphoma.

010

Ajay Major, MD, MBA @majorajay.bsky.social · 06/05/2026

ctDNA TRANSFORM #lymsm - MRDneg = longer EFS at all timepoints - more pts achieved MRDneg with liso-cel v SOC - among MRDneg pts liso-cel ⬆️ EFS, PFS, DOR - MRD re-emergence 1 yr: 0/20 liso-cel v 9/15 ASCT - ctDNA prognostic independent of PET Role for ctDNA+PET post-CAR? ascopubs.org/doi/pdf/10.1...

010

Ajay Major, MD, MBA @majorajay.bsky.social · 06/05/2026

NAVD real-world outcomes #lymsm - 327 pts, med age 37, 24% ≥60 yrs - ORR 94% (CR 86%) - 1-yr PFS 94.5%, OS 99.7% - irAEs in 29% (9% G3+) - febrile neutropenia 10%, infections 25% (10% G3+) RW efficacy mirrors S1826, tho notably⬆️ infections (despite GCSF) & irAEs. pmc.ncbi.nlm.nih.gov/articles/PMC...

000

Reposted by Ajay Major, MD, MBA

International Society for Cutaneous Lymphomas @cutaneouslymphomas.bsky.social · 27/04/2026

Spotlight on Dr. Brad Haverkos, Associate Professor at the University of Colorado, specializing in T/NK-cell lymphoma & immunotherapy. He leads a multidisciplinary clinic and clinical trials program advancing targeted care. Passionate about team-based innovation in lymphoma research.

011

Ajay Major, MD, MBA @majorajay.bsky.social · 22/04/2026

Mosun/pola R/R MCL #lymsm - 42 pts, 26% prior CAR, 48% TP53mut - ORR 88% (CR 79%) - mPFS 19 mos, mOS 21 mos - prior CAR: ORR 91% (CR 82%) - 43% CRS (all G1-2), 5 G5 AEs, all infection-related Great activity in TP53mut and post-CAR in challenging R/R setting. ashpublications.org/blood/articl...

020

Ajay Major, MD, MBA @majorajay.bsky.social · 21/04/2026

Come join us on Saturday, May 2 for the @bloodcancerunited.bsky.social 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm bloodcancerunited.org/RMBCC26

010

Ajay Major, MD, MBA @majorajay.bsky.social · 16/04/2026

Stage IA NLPHL outcomes - 779/2243 pts Stage IA - completely resected: better PFS if +RT - unresected: R monotx & ABVD with worse PFS as compared to RT +/- ABVD - not enough N to analyze R-CHOP RT alone great option in both resected & unresected dx. #lymsm ashpublications.org/bloodadvance...

000

Ajay Major, MD, MBA @majorajay.bsky.social · 10/03/2026

New anatomic classification R/R SCNSL - 162 pts, 42 with both CNS+systemic dx - leptomeningeal dx = inferior OS in MV model - 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve) Useful schema in future trials. #lymsm onlinelibrary.wiley.com/doi/10.1002/...

000

Ajay Major, MD, MBA @majorajay.bsky.social · 09/03/2026

Glofitamab CNS penetration @bloodadvances.bsky.social - 8 PCNSL/SCNSL, 7 LBCL, 1 BL - 3/8 CRS (all G1-2), no ICANS - 7/8 response (4 CR, 3 PR) - 2 PCNSL durable CRs - CSF: +glofi with activity in vitro Bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm ashpublications.org/bloodadvance...

021

Ajay Major, MD, MBA @majorajay.bsky.social · 09/03/2026

Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm

020